CD274 and neoplasm: Administration of AMD3100, an inhibitor of chemokine receptor 4, a CXCL12 receptor has reversed the CAF-induced immune suppression and synergizes with anti-PD-L1, achieved superior tumor control in a pancreatic tumor model (127).